CN112218871B - 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用 - Google Patents

噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用 Download PDF

Info

Publication number
CN112218871B
CN112218871B CN201980037798.8A CN201980037798A CN112218871B CN 112218871 B CN112218871 B CN 112218871B CN 201980037798 A CN201980037798 A CN 201980037798A CN 112218871 B CN112218871 B CN 112218871B
Authority
CN
China
Prior art keywords
compound
alkyl
isomer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980037798.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN112218871A (zh
Inventor
郑晓平
江志赶
贺海鹰
李婕
龚珍
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN112218871A publication Critical patent/CN112218871A/zh
Application granted granted Critical
Publication of CN112218871B publication Critical patent/CN112218871B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
CN201980037798.8A 2018-06-05 2019-06-05 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用 Active CN112218871B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018105707197 2018-06-05
CN201810570719 2018-06-05
CN201811033469 2018-09-05
CN201811033469X 2018-09-05
PCT/CN2019/090164 WO2019233443A1 (zh) 2018-06-05 2019-06-05 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用

Publications (2)

Publication Number Publication Date
CN112218871A CN112218871A (zh) 2021-01-12
CN112218871B true CN112218871B (zh) 2022-10-18

Family

ID=68770078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980037798.8A Active CN112218871B (zh) 2018-06-05 2019-06-05 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用

Country Status (5)

Country Link
US (1) US11680070B2 (ja)
EP (1) EP3805230A4 (ja)
JP (1) JP7275444B2 (ja)
CN (1) CN112218871B (ja)
WO (1) WO2019233443A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787166A (zh) * 2019-12-05 2022-07-22 漳州片仔癀药业股份有限公司 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7265681B2 (ja) * 2019-12-05 2023-04-26 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 Ａｃｃ１及びａｃｃ２阻害剤としての結晶形及びその製造方法並びに使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003262946A1 (en) * 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
EP2351743A4 (en) * 2008-10-27 2012-05-09 Takeda Pharmaceutical BICYCLIC CONNECTION
PL2776038T3 (pl) * 2011-11-11 2018-06-29 Gilead Apollo, Llc Inhibitory acc i ich zastosowania
JP6417401B2 (ja) * 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
JP6417402B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
WO2017147161A1 (en) * 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787166A (zh) * 2019-12-05 2022-07-22 漳州片仔癀药业股份有限公司 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用
CN114787166B (zh) * 2019-12-05 2023-09-19 漳州片仔癀药业股份有限公司 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用

Also Published As

Publication number Publication date
US20210238190A1 (en) 2021-08-05
CN112218871A (zh) 2021-01-12
JP7275444B2 (ja) 2023-05-18
JP2021525784A (ja) 2021-09-27
EP3805230A4 (en) 2022-03-02
WO2019233443A1 (zh) 2019-12-12
EP3805230A1 (en) 2021-04-14
US11680070B2 (en) 2023-06-20

Similar Documents

Publication Publication Date Title
CN112105610A (zh) 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
JP7333342B2 (ja) ２，３－ジヒドロ－１ｈ－ピロリジン－７－ホルムアミド誘導体およびその使用
BR112021004269A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo, relacionada à proteína crbn e método para tratamento da mesma
JP2024505735A (ja) 置換されたピリダジンフェノール系誘導体
CN112218871B (zh) 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用
CN114174282A (zh) 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
WO2023280280A1 (zh) 作为KRas G12D抑制剂的稠环化合物
CN114728967A (zh) 作为jak抑制剂的三并杂环类化合物及其应用
CN113754654A (zh) 咪唑并吡啶类化合物及其用途
PT1966217E (pt) Novos derivados de furopirimidina acíclicos substituídos e sua utilização para o tratamento de doenças cardiovasculares
CN116964058A (zh) Kras g12d抑制剂及其在医药上的应用
CN115677688A (zh) 1,5-萘啶酮类化合物
CN114555600A (zh) 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物
WO2021038490A1 (en) Substituted urea dihydroorotate dehydrogenase inhibitors
CN111699175A (zh) 前列环素受体受体激动剂
JP7227427B2 (ja) Ｓｇｌｔ２／ｄｐｐ４阻害剤及びその使用
CN113811530B (zh) 作为糜酶抑制剂的嘧啶酮类化合物及其应用
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
CA3209693A1 (en) Substituted pyridine-2,4-dione derivatives
ES2924182T3 (es) Derivados de benzofurano y su uso como inhibidores de bromodominio
CN115003672A (zh) 喹啉并咪唑类化合物及其应用
CN111356692B (zh) Ido抑制剂
CN117279923A (zh) 六元杂芳并脲环的衍生物及其应用
WO2016034637A1 (fr) Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques comme inhibiteurs de la ftl3 et jak
CN113286594A (zh) 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: 210032 room 218, business office building, building 9, Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

CB02 Change of applicant information
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045136

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant